A blood test that screens for more than 50 cancers – and which is being trialled in the NHS – is correct in 62 per cent of cases where it thinks people may have the disease, a study has found.
The Galleri test, which can be given annually, looks for the “fingerprint” of dozens of deadly cancers, often picking up signs before symptoms even appear.
It works by identifying DNA in the bloodstream that has been shed by cancer cells, giving the earliest signs somebody may have the disease.
Now, a key US trial on the test has shown that Galleri is highly accurate in ruling out cancer in people without the disease, while also picking up cancer cases at an early stage, when the disease is more treatable.
Of those people found to have a “cancer signal” detected in their blood, 61.6 per cent went on to be diagnosed with cancer, the findings of the Pathfinder 2 study showed.
And in 92 per cent of cases, the test could pinpoint in which organ or tissue the cancer arose, meaning time and money could be saved on other scans and other tests.
More than half of the new cancers detected by Galleri in the study were the earliest stage I or II, while more than two-thirds were detected at stages I-III.
Galleri, which has been dubbed the holy grail of cancer tests, also correctly ruled out cancer in 99.6 per cent of people who did not have the disease.
The findings are being presented at the European Society for Medical Oncology (ESMO) Congress in Berlin.
Sir Harpal Kumar, president of International Business and BioPharma at Grail, which pioneered Galleri, and former head of Cancer Research UK, said the findings were impressive.
“We’re really very excited and we think this is a further step along the way in really transforming cancer outcomes,” he said.
The Pathfinder 2 study looked at how the Galleri test may be used in a real-world setting, alongside regular screening programmes for things like breast and bowel cancer.
People from the US and Canada with no symptoms were recruited, of which 23,161 were analysed and had a follow-up period of at least 12 months.
The results suggested that adding Galleri to regular cancer screening led to a more than seven-fold increase in the number of cancers found within a year.
The test detected a cancer signal in 216 people, and cancer was diagnosed in 133 of these.
Therefore, the likelihood of receiving a cancer diagnosis following a positive test result showing a “cancer signal” was 61.6 per cent.
An NHS Galleri trial on how well the test works in screening people without symptoms is expected to be published in the middle of next year.
Sir Harpal said the fact the test can also pinpoint which organ or tissue the cancer is in makes the “diagnostic process very efficient and quick”.
Galleri can also aid doctors treating patients who may have vague symptoms.
With PA
Hence then, the article about holy grail cancer test finds signs before symptoms appear was published today ( ) and is available on inews ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ‘Holy grail’ cancer test finds signs before symptoms appear )
Also on site :
- 2 dead in crash, US 287 closed in Larimer County: CSP
- SZA Praises Reneé Rapp’s Harp-Backed ‘Good Days’ Cover
- From barracks to palace: Soldiers who led military coups to become state leaders